Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus reuteri TSR332
- Development stage
- Preclinical
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus reuteri TSR332 is a probiotic bacterial strain isolated from the healthy human gut and developed by Glac Biotech. It is being investigated for the management of hyperuricemia and gout. The strain's primary mechanism of action involves the assimilation of purine nucleosides, specifically inosine and guanosine, within the gastrointestinal tract. By consuming these precursors, TSR332 reduces the amount of purines available for absorption and subsequent conversion into uric acid by the liver, thereby lowering serum uric acid levels. Preclinical studies in rat models have shown that long-term supplementation with TSR332 effectively stabilizes uric acid levels without adverse effects on renal function or body weight. It has also been evaluated in human pilot trials, both as a monotherapy and in combination with other probiotic strains, to improve purine metabolism and liver function.
- Other names
- Lactobacillus reuteri TSR332
Beyond the preview
Go deeper on Lactobacillus reuteri TSR332.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus reuteri TSR332.